CG Oncology

Today we are proud to announce the initiation of our Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer (#NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) and meet certain program eligibility criteria. The first patient has been dosed in the EAP, and enrollment is ongoing. 📄 Read the full release here: https://bit.ly/3Rv5a7C Healthcare providers and bladder cancer patients who are interested to learn more about CG Oncology’s EAP including eligibility criteria may visit www.clinicaltrials.gov, NCT06443944, or contact EAP@cgoncology.com. #BladderCancer #ClinicalTrials #UroOncology #Immunotherapy #PatientCare #DrugDevelopment #Immunotherapy #Therapeutics #CGOncology #cretostimogene

NEWS ALERT: Our team just presented the latest Phase 3 BOND-003 data on cretostimogene grenadenorepvec, our investigational oncolytic immunotherapy, at the Society of Urologic Oncology, Inc #SUO2024, highlighting its potential as a novel treatment for BCG-unresponsive #NMIBC. Cretostimogene continues to show both promising efficacy and safety data with 74.5% of patients achieving a complete response at any time. Designed to selectively target tumor cells while sparing healthy tissue, cretostimogene has the potential to transform bladder cancer care and address critical unmet need, if approved by the FDA. Learn more about this milestone here: https://bit.ly/41fvcBG #SUO #SUO24 #BladderCancer #Urology #Biotech

Hear from Sia Daneshmand, M.D., Professor of Urology (Clinical Scholar), Director of Clinical Research at the Keck School of Medicine of the University of Southern California as he highlights why the #bladdercancer community needs better treatment options. Cretostimogene grenadenorepvec, our lead candidate, is an oncolytic immunotherapy with a dual mechanism of action that selectively replicates in and lyses cancer cells while simultaneously amplifying the immune response against bladder tumors. Upon potential FDA approval, we believe its novel MOA has the potential to fill the treatment gap for patients. #Urology #BladderCancer

We’re just a few days out from the Society of Urologic Oncology, Inc #SUO2024 in Dallas, Texas!     We look forward to sharing insights on our lead candidate, cretostimogene grenadenorepvec, and its potential to advance BCG-unresponsive #NMIBC treatment if approved by the FDA.     Join us on Thursday, Dec. 5 at 11:45 for the updated results from our Phase 3, BOND-003 study data.     Learn more about our participation here: https://bit.ly/4ir7o42   #SUO24 #SUO #BladderCancer #Urology 

➡️New Opportunity Alert.📢 CG Oncology has a great opportunity for a Remote/US Based Manager of Clinical Monitoring. This dynamic individual will be responsible for Implementing strategies for in-house, regional monitoring activities on assigned studies applying a risk-based approach when indicated as well as review and finalize visit reports for regional CRAs managed by CG Oncology. Click the link below to learn more https://lnkd.in/efbyQHrS

Despite progress in #bladdercancer treatment, several gaps persist in treating patients with High-Risk BCG-unresponsive #NMIBC. Hear from Sima Porten, MD, MPH, Associate Professor in Residence at UCSF, as she analyzes the current treatment landscape. #Urology #BladderCancer

At CG Oncology we have a lot to be grateful for on Thanksgiving and all year round. We have a talented team that pursues our mission with passion every day. However, our work would not be possible without the patients who participate in our clinical trials, as well as the investigators and their staff who conduct them. We truly appreciate their contributions to research!

Did you know? #BladderCancer is the 6th most common cancer in the United States, with an estimated 83,000 new cases in 2024. Our investigational drug, cretostimogene grenadenorepvec, is designed to treat patients with BCG-unresponsive non-muscle invasive bladder cancer (#NMIBC) – which represents 75% of all new bladder cancer cases. Learn more: https://bit.ly/48IZnmi #Urology

CG Oncology is excited to announce & welcome our newest additions to the team: Wofe' Cornwall - Sr. Director, National & Strategic Accounts - Head of Payers Andrea Strong, - Medical Science Liaison David Dai - Sr. Director, Pricing & Strategy Mike Swift, CPA, MBA - Sr. Manager, Financial Planning & Analysis Kristen Scholz - Vice President, Medical Affairs Ian Oldham - Director, Regulatory Operations

Hear from Ashish Kamat, MD, MBBS, Endowed Professor of Urologic Oncology (Surgery) and Cancer Research at The University of Texas MD Anderson Cancer Center as he discusses the unmet need in the U.S. for a bladder-sparing therapy for patients who are unresponsive or cannot access BCG. #BladderCancer #Urology